ERBB2 and neoplasm: A feasibility study of neoadjuvant talazoparib administered prior to neoadjuvant chemotherapy in patients with gBRCA1/2m and HER2-negative BC reported decreases in tumour volume (median 88%; range 30–98%) in all 13 patients after 2 months of therapy.90 These promising results led to the ongoing phase II study of single-agent talazoparib, with results expected in 2018 (NCT02282345).91 In addition, several PARPi are currently in phase II/III studies for adjuvant or neoadjuvant therapy in women with TNBC or HER2-negative BC and gBRCA1/2m, as described in Table 3.